Pharmacological alteration of bile acid metabolism or bile acid signaling pathways such as using bile acid receptor agonists or bile acid binding resins may be a promising therapeutic strategy for the treatment of obesity and diabetes. The gene discussed is NR1H4; the disease is obesity due to melanocortin 4 receptor deficiency.